KOREA UNITED PHARM INC
Prescription drugmaker specializing in incrementally modified drugs such as Cilostan CR, exporting to about 40 countries.
As of 2026-10-11, KOREA UNITED PHARM INC has 289 Korean MFDS drug approvals, 26 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1987 and listed on KOSPI in 2007, the company is a prescription drug manufacturer specializing in incrementally modified drugs (IMDs). It produces about 200 products including the IMDs Cilostan CR, Atmax Combi Gel, and Gastin CR, manufacturing solid dosage forms, injectables, anticancer drugs, and inhalers across its Sejong 1 and 2 plants. In 2025 it recorded revenue of KRW 288.8 billion with a 17% operating margin, exported 10% of sales to about 40 countries, and invested over 12% of revenue in R&D, resulting in a total of 18 IMDs and reformulated products launched to date.
Products & technology
- Cilostan CRIncrementally modified drug
- Atmax Combi GelIncrementally modified drug
- Gastin CRIncrementally modified drug
Regulatory approvals
data.go.kr289 Korean MFDS drug approvals · 1976–2026
- MFDS drugEDOBAN Tab. 30mg2026-08-25Drug · Prescription · Approval202602483
- MFDS drugEDOBAN Tab. 15mg2026-08-25Drug · Prescription · Approval202602484
- MFDS drugEDOBAN Tab. 60mg2026-08-05Drug · Prescription · Approval202602261
- MFDS drugSERETEROL ACTIVAIR Inhalation Powder 250/50(Fluticasone Propionate, Salmeterol)2026-06-02Drug · Prescription · Approval202601599
- MFDS drugFENODUO Cap.2026-05-28Drug · Prescription · Approval202601552
- MFDS drugAzafrine Tab. 12.5mg2026-02-13Drug · Prescription · Approval202600436
- MFDS drugAlkafen Speed Soft Capsule2026-02-03Drug · OTC · Approval202600296
- MFDS drugAlkafen Nasal A Soft Capsule2026-01-15Drug · OTC · Notification202600145
- MFDS drugATMEG CombiGel softcaps. 20/1000mg2026-01-06Drug · Prescription · Approval202600039
- MFDS drugCilo Duo CR Tab. 200/20mg2025-08-27Drug · Prescription · Approval202502256
- MFDS drugCilo Duo CR Tab. 200/10mg2025-08-27Drug · Prescription · Approval202502257
- MFDS drugPITARIC Cap.2025-05-29Drug · Prescription · Approval202501335
Show 68 more
- MFDS drugGinkona Tab.2024-10-16Drug · OTC · Notification202402444
- MFDS drugROSUMEG CombiGel Soft Cap. 10/1000mg(Rosuvastatin, Omega-3-acid ester 90)2024-04-25Drug · Prescription · Approval202400974
- MFDS drugDAUNOCIN Inj. 20mg2024-03-25Drug · Prescription · Approval202400632
- MFDS drugNewjenta CR Tab.2024-03-05Drug · Prescription · Approval202400470
- MFDS drugIrino injection2024-01-11Drug · Prescription · Approval202400089
- MFDS drugthymofle2024-01-04Drug · Prescription · Approval202400027
- MFDS drugROSUMEG CombiGel Soft Cap.2023-12-19Drug · Prescription · Approval202303366
- MFDS drugGADOVA2023-11-09Drug · Prescription · Approval202303106
- MFDS drugRABEMINI Tab.2023-10-18Drug · Prescription · Approval202302938
- MFDS drugVIATIN M Tab.2023-06-30Drug · Prescription · Approval202302026
- MFDS drugATMEG CombiGel softcaps. 2.5/1000mg2022-12-01Drug · Prescription · Approval202204318
- MFDS drugDapaU Tab.2022-08-19Drug · Prescription · Approval202203322
- MFDS drugATMEG CombiGel softcaps. 5/1000mg2022-07-21Drug · Prescription · Approval202203038
- MFDS drugRABEDUO Tab2022-01-28Drug · Prescription · Approval202200514
- MFDS drugHealus Tab. 50mg2022-01-10Drug · Prescription · Approval202200168
- MFDS drugHealusmet Tabs. 50/500 mg2021-10-18Drug · Prescription · Approval202106959
- MFDS drugCorobin Activair2021-07-13Drug · Prescription · Approval202105306
- MFDS drugKorea United Vancomycine Hydrochloride Inj. 1g2021-01-29Drug · Prescription · Notification202100940
- MFDS drugAlkafen Speed Soft CapsuleRevoked2021-01-25Drug · OTC · Approval202100762
- MFDS drugATMEG CombiGel softcaps.2021-01-21Drug · Prescription · Approval202100664
- MFDS drugViatin Tablet 50 mg2021-01-08Drug · Prescription · Approval202100172
- MFDS drugEZETOVA Tab 10/10 mg2021-01-08Drug · Prescription · Approval202100182
- MFDS drugEZETOVA Tab 10/40 mgRevoked2021-01-08Drug · Prescription · Approval202100180
- MFDS drugEZETOVA Tab 10/20 mgRevoked2021-01-08Drug · Prescription · Approval202100181
- MFDS drugAlkafen Nasal A Soft CapsuleRevoked2020-12-14Drug · OTC · Notification202008743
- MFDS drugCered Inj.Revoked2020-10-13Drug · Prescription · Notification202006966
- MFDS drugVancozin Cap. 125mg2020-08-27Drug · Prescription · Approval202006034
- MFDS drugResoid Tab. 1mgRevoked2020-08-18Drug · Prescription · Approval202005840
- MFDS drugResoid Tab. 2mgRevoked2020-08-18Drug · Prescription · Approval202005841
- MFDS drugKorea United Dactinomycin Injection2020-07-22Drug · Prescription · Approval202005256
- MFDS drugUsosan Tab. 100mgRevoked2020-07-10Drug · OTC · Notification202005007
- MFDS drugThiodan Tab. 32.5mg2020-07-02Drug · Prescription · Approval202004829
- MFDS drugGlicetil Tab.2020-04-28Drug · Prescription · Approval202003156
- MFDS drugPrephentin Tab. 75mg2020-04-27Drug · Prescription · Approval202003059
- MFDS drugTamstro SR Tab. 0.4mg2020-04-17Drug · Prescription · Approval202002725
- MFDS drugPrephentin Tab. 150mg2020-04-10Drug · Prescription · Approval202002552
- MFDS drugDoneptin Tab. 10mg2020-04-03Drug · Prescription · Approval202002345
- MFDS drugDoneptin Tab. 5mg2020-04-03Drug · Prescription · Approval202002346
- MFDS drugLomin Comp Syrup.2020-03-13Drug · Prescription · Approval202001761
- MFDS drugFegout Tab. 40mg2020-01-31Drug · Prescription · Approval202000520
- MFDS drugEldotein Tabs.2020-01-13Drug · OTC · Notification202000200
- MFDS drugViatin Tablet 100 mg2020-01-03Drug · Prescription · Approval202000060
- MFDS drugKorea United Azathioprine Tab. 50mg2019-09-26Drug · Prescription · Approval201906852
- MFDS drugFenorics EH Tab.2019-06-28Drug · Prescription · Approval201904452
- MFDS drugPiosk Tab. 15mg2019-06-27Drug · Prescription · Approval201904418
- MFDS drugOMETHYL CUTIELET(Omega-3-acid ethylesters 90)2019-04-15Drug · Prescription · Approval201902306
- MFDS drugGlicetil Syrup2019-03-29Drug · Prescription · Approval201901960
- MFDS drugTiglor Tab. 90mg2019-03-15Drug · Prescription · Approval201901595
- MFDS drugKalomin Syrup2019-02-27Drug · OTC · Approval201901219
- MFDS drugTiglor Tab. 60mg2019-02-21Drug · Prescription · Approval201901067
- MFDS drugKalomin S Tab.2019-01-09Drug · Prescription · Notification201900093
- MFDS drugTamiselva Cap. 45mgRevoked2018-04-05Drug · Prescription · Approval201801499
- MFDS drugTamiselva Cap. 30mgRevoked2018-04-05Drug · Prescription · Approval201801500
- MFDS drugUnitib Tab. 100mg2018-03-30Drug · Prescription · Approval201801437
- MFDS drugUnigrel CR Tab.2018-02-23Drug · Prescription · Approval201800910
- MFDS drugClavixin Duo Cap. 75/75mg2018-02-08Drug · Prescription · Approval201800764
- MFDS drugAzafrine Tab. 25mg2017-12-21Drug · Prescription · Approval201708459
- MFDS drugFovead Tab.2017-12-21Drug · Prescription · Approval201708476
- MFDS drugCorbi C Inj.Revoked2017-12-13Drug · Prescription · Notification201708355
- MFDS drugDexima Tab.2017-11-30Drug · Prescription · Approval201708195
- MFDS drugFegout Tab. 80mg2017-10-27Drug · Prescription · Approval201707620
- MFDS drugPlatinox Inj.2017-08-14Drug · Prescription · Approval201706577
- MFDS drugTezomin Inj. 2.5mg2017-06-20Drug · Prescription · Approval201704494
- MFDS drugLevotics CR Tab.2017-04-12Drug · Prescription · Approval201701832
- MFDS drugTeramopine Tab. 80/5mg2017-03-31Drug · Prescription · Approval201701558
- MFDS drugTeramopine Tab. 40/5mg2017-01-20Drug · Prescription · Approval201700389
- MFDS drugCilostan CR Tab. 100mg2016-12-30Drug · Prescription · Approval201607419
- MFDS drugErlotib Tab. 100mg2016-10-28Drug · Prescription · Approval201606331
Showing the 80 most recent of 289 records.
Clinical trials
data.go.kr130 MFDS clinical trial authorisations · 2012–2026 (Bioequivalence 64 · Phase 1 50 · Phase 3 13 · Phase 2 2 · Phase 4 1)
- Phase 1UI0872026-09-09
2 trial sites
- Phase 1UIC202603, UIC2026042026-07-14
2 trial sites
- Phase 1UI0592026-06-23
1 trial site
- Phase 1UIC202601, UIC2026022026-05-04
2 trial sites
- BioequivalenceUG25022026-03-05
1 trial site
- BioequivalenceUG25022026-03-03
1 trial site
- Phase 3UI1222026-01-20
20 trial sites
- Phase 1UIC202502, UIC2025052025-07-30
2 trial sites
- Phase 1UG22012025-06-30
2 trial sites
- Phase 1UI0872025-06-19
2 trial sites
- Phase 1UIC202007, UIC202306, UIC2023072025-06-19
1 trial site
- BioequivalenceUG22022025-06-10
2 trial sites
Show 68 more
- Phase 1UI1112025-03-27
2 trial sites
- Phase 1UI0282025-02-19
2 trial sites
- Phase 1UI1112024-12-09
2 trial sites
- BioequivalenceUI0092024-10-09
2 trial sites
- BioequivalenceUG24012024-10-09
2 trial sites
- Phase 1UI0592024-08-08
1 trial site
- Phase 1UI1002024-07-16
2 trial sites
- Phase 3UI0282024-05-07
17 trial sites
- Phase 1UIC202007, UIC202306, UIC2023072024-04-09
1 trial site
- BioequivalenceUG22022024-03-29
2 trial sites
- Phase 1UIC202304, UIC2023052023-09-18
2 trial sites
- Phase 1UI0592023-08-07
1 trial site
- BioequivalenceUI0092023-06-02
2 trial sites
- Phase 1UI0682023-02-01
2 trial sites
- Phase 1UI0682023-01-25
2 trial sites
- Phase 3UIC202007, UIC202306, UIC2023072023-01-11
25 trial sites
- Bioequivalence우소산정200mg(우르소데옥시콜산)2022-12-14
2 trial sites
- Phase 1UI0612022-11-11
2 trial sites
- Phase 1UIC202007, UIC202306, UIC2023072022-10-31
1 trial site
- Bioequivalence로수맥콤비젤연질캡슐2022-06-14
2 trial sites
- Phase 1UI0402022-06-09
2 trial sites
- Phase 1UI0162022-05-10
2 trial sites
- Phase 3UI0742022-03-04
6 trial sites
- Phase 1UIC202007, UIC202306, UIC2023072022-01-14
1 trial site
- Phase 1UI0612022-01-11
2 trial sites
- Phase 1UI0182021-08-19
2 trial sites
- Bioequivalence에소놀캡슐40mg(에스오메프라졸마그네슘이수화물)2021-06-14
2 trial sites
- Phase 2UI0302021-05-28
4 trial sites
- BioequivalenceUI0092021-05-25
2 trial sites
- Phase 1UI0612021-04-28
2 trial sites
- Bioequivalence글리진정10밀리그램2021-03-02
2 trial sites
- Phase 1UI058, UIC2020042021-02-03
2 trial sites
- Bioequivalence로수맥콤비젤연질캡슐2021-02-03
2 trial sites
- Phase 1UIC202007, UIC202306, UIC2023072020-12-18
1 trial site
- Phase 1UI0362020-07-02
1 trial site
- Phase 1UIC202001, UIC2020022020-07-02
1 trial site
- Phase 1UN042020-05-11
1 trial site
- Phase 3UI0632020-01-17
8 trial sites
- Bioequivalence에제토바정 10/20밀리그램2020-01-06
2 trial sites
- Phase 1UIC201903,UIC2019042019-12-17
1 trial site
- Bioequivalence유나잘탄정5/160밀리그램2019-12-10
2 trial sites
- Bioequivalence유나잘탄정5/80밀리그램2019-12-10
2 trial sites
- Bioequivalence힐러스메트정50/500밀리그램2019-10-14
2 trial sites
- Phase 1UI0302019-10-01
2 trial sites
- Bioequivalence힐러스정50밀리그램(빌다글립틴)2019-09-06
2 trial sites
- Bioequivalence프레펜틴정150밀리그램(프레가발린)2019-07-29
2 trial sites
- Phase 3UI0282019-04-29
4 trial sites
- Phase 1UI0282019-01-24
2 trial sites
- Phase 1UI0182018-11-15
1 trial site
- Phase 3UI022, UI0232018-11-07
43 trial sites
- Phase 1UI0372018-10-15
1 trial site
- Phase 1UI022, UI0232018-07-05
1 trial site
- Bioequivalence덱시마정2018-07-02
2 trial sites
- Phase 1UI0142018-05-25
1 trial site
- Phase 1UI0142018-05-24
1 trial site
- Bioequivalence오메가-3-산에틸에스테르90 2g2018-03-20
2 trial sites
- Bioequivalence오메가-3-산에틸에스테르90 1g2018-03-20
2 trial sites
- Phase 1UI0262017-07-17
1 trial site
- Phase 3UI0262017-07-13
6 trial sites
- Phase 1UI0142017-07-13
1 trial site
- Phase 3UI0182017-06-22
22 trial sites
- Phase 1UI0282017-05-12
1 trial site
- Phase 2UI0262017-04-26
6 trial sites
- Bioequivalence덱시마정2017-04-21
2 trial sites
- Bioequivalence글리세틸시럽(콜린알포세레이트)2017-03-31
2 trial sites
- Bioequivalence세페신정(세페타메트피복실염산염)(제제개선 후)2017-03-06
2 trial sites
- Phase 1UI022, UI0232017-02-27
1 trial site
- Bioequivalence페고트정80밀리그램(페북소스타트)2017-02-17
2 trial sites
Showing the 80 most recent of 130 records.
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1 · Recruiting · 2026-07 · NCT07682948
Phase 1 · Not yet recruiting · 2026-07 · NCT07727629
Phase 1 · Not yet recruiting · 2026-04 · NCT07548957
Phase 1 · Recruiting · 2025-08 · NCT07162441
Phase 1 · Completed · 2025-02 · NCT07691268
Phase 1 · Completed · 2024-10 · NCT07110740
Phase 1 · Unknown · 2024-07 · NCT06393881
Phase 1 · Completed · 2023-10 · NCT06141577
Phase 1 · Completed · 2023-09 · NCT07735052
Phase 1 · Completed · 2023-03 · NCT06141590
Show 11 more trials
Phase 2 · Unknown · 2021-11 · NCT05055414
Phase 1 · Unknown · 2021-09 · NCT05085184
Phase 1 · Completed · 2021-02 · NCT05282914
Phase 3 · Completed · 2019-03 · NCT07600385
Phase 1 · Completed · 2017-03 · NCT06568133
Phase 1 · Completed · 2016-05 · NCT05190133
Phase 4 · Terminated · 2015-08 · NCT04664803
Phase 3 · Completed · 2014-11 · NCT03225248
Phase 1 · Completed · 2014-06 · NCT02166398
Phase 3 · Completed · 2013-08 · NCT02151734
Phase 1 · Completed · 2011-09 · NCT01841086
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Formulation and evaluation of carrier-based dry powders containing budesonide and arformoterol for inhalation therapy.
Pharmaceutical development and technology · 2024-11 · Oh DW, Choi JH, Yu GH 외 7
- NIR-Guided Coating Optimization of Omega-3 Fatty Acid Mini Soft Capsules with Pitavastatin and Ezetimibe.
Pharmaceutics · 2024-10 · Han HR, Choi JH, Yoo JH 외 5
- 13-Week Repeated Oral Toxicity and Toxicokinetic Studies of Rabeprazole Sodium and Sodium Bicarbonate Combination in Dogs.
International journal of toxicology · 2024-01 · Roh JS, Nam KY, Jung WT 외 3
- Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Omega-3-Acid Ethyl Esters and the Corresponding Loose Combination in Healthy Korean Male Subjects.
Drug design, development and therapy · 2024-01 · Khwarg J, Lee S, Jang IJ 외 14
- Safety and pharmacokinetic comparison between fenofibric acid 135 mg capsule and 110 mg enteric-coated tablet in healthy volunteers.
Translational and clinical pharmacology · 2023-06 · Seo YB, Kim JH, Song JH 외 13
- Safety and effectiveness of 4-week therapy with aceclofenac controlled release once a day.
Scientific reports · 2022-10 · Jeong JC, Chung YH, Park T 외 5
- Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers.
Pharmaceuticals (Basel, Switzerland) · 2022-08 · Kim JH, Sunwoo J, Song JH 외 8
- Bioanalytical methods for the detection of duloxetine and thioctic acid in plasma using ultra performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS).
Translational and clinical pharmacology · 2022-06 · Wei Z, Jeong HC, Kang YJ 외 3
- Evaluation of food effects on the pharmacokinetics of Pelargonium sidoides and Coptis with each bioactive compound berberine and epicatechin after a single oral dose of an expectorant and antitussive agent UI026 in healthy subjects.
Translational and clinical pharmacology · 2022-03 · Park Y, Jung W, Yang E 외 8
- Oleanane triterpenoids from Rubia philippinensis and their inhibitory effect on 20-HETE synthesis.
Natural product research · 2021-04 · Quan KT, Min BG, Hwang IH 외 3
Show 16 more publications
- Systematic Target Screening Revealed That Tif302 Could Be an Off-Target of the Antifungal Terbinafine in Fission Yeast.
Biomolecules & therapeutics · 2021-03 · Lee S, Nam M, Lee AR 외 10
- Effects of Pelargonium sidoides and Coptis Rhizoma 2 : 1 Mixed Formula (PS + CR) on Ovalbumin-Induced Asthma in Mice.
Evidence-based complementary and alternative medicine : eCAM · 2020-01 · Min BG, Park SM, Choi YW 외 8
- Double controlled release of highly insoluble cilostazol using surfactant-driven pH dependent and pH-independent polymeric blends and in vivo bioavailability in beagle dogs.
International journal of pharmaceutics · 2019-03 · Nam KY, Cho SM, Choi YW 외 4
- Simultaneous analysis of acetylcarnitine, proline, hydroxyproline, citrulline, and arginine as potential plasma biomarkers to evaluate NSAIDs-induced gastric injury by liquid chromatography-tandem mass spectrometry.
Journal of pharmaceutical and biomedical analysis · 2019-02 · Shin S, Jeong HM, Chung SE 외 10
- Spiral mouthpiece design in a dry powder inhaler to improve aerosolization.
International journal of pharmaceutics · 2018-12 · Lee HJ, Kwon IH, Lee HG 외 8
- Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial.
Gut and liver · 2018-09 · Yoon H, Lee DH, Lee YH 외 19
- Pharmacokinetics and Anti-Gastric Ulceration Activity of Oral Administration of Aceclofenac and Esomeprazole in Rats.
Pharmaceutics · 2018-09 · Kim TH, Thapa SK, Lee DY 외 10
- Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet.
Drug design, development and therapy · 2018-01 · Lee S, Nam KY, Oh J 외 6
- Combination of Pelargonium sidoides and Coptis chinensis root inhibits nuclear factor kappa B-mediated inflammatory response in vitro and in vivo.
BMC complementary and alternative medicine · 2018-01 · Park SM, Min BG, Jung JY 외 8
- Comparison of pharmacokinetic characteristics of sildenafil citrate chewable tablets and film-coated tablets in healthy male subjects.
Translational and clinical pharmacology · 2017-09 · Yoo H, Cho SM, Choi YW 외 6
- Modulation of microenvironmental pH for dual release and reduced in vivo gastrointestinal bleeding of aceclofenac using hydroxypropyl methylcellulose-based bilayered matrix tablet.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2017-05 · Kang WH, Nguyen HV, Park C 외 2
- Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
Pharmaceutical research · 2016-03 · Thao le Q, Byeon HJ, Lee C 외 7
- Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study.
Drug design, development and therapy · 2016-01 · Choi Y, Lee S, Cho SM 외 4
- In vitro and in vivo correlation of disintegration and bitter taste masking using orally disintegrating tablet containing ion exchange resin-drug complex.
International journal of pharmaceutics · 2013-10 · Kim JI, Cho SM, Cui JH 외 3
- End point determination of blending process for trimebutine tablets using principle component analysis (PCA) and partial least squares (PLS) regression.
Archives of pharmacal research · 2012-09 · Lee SH, Lee JH, Cho S 외 2
- Content uniformity in granules for aceclofenac controlled release (CR) tablets determined using near-infrared spectroscopy and wide area illumination (WAI) Raman spectroscopy.
Archives of pharmacal research · 2012-02 · Woo YA
Patents
KIPRIS · applicant-matchedPublished · 2026-04 · Application 1020260071541
PCT · Published · 2025-05 · Application PCT/KR2025/006670
Published · 2025-02 · Application 1020250022712
Published · 2024-11 · Application 1020240174585
PCT · Published · 2024-10 · Application PCT/KR2024/015387
Published · 2024-05 · Application 1020240066394
PCT · Published · 2024-01 · Application PCT/KR2024/000667
Published · 2023-11 · Application 1020230153880
Published · 2023-11 · Application 1020230153900
Published · 2023-11 · Application 1020230153925
Show 261 more patents
Published · 2023-11 · Application 1020230149859
Published · 2023-10 · Application 1020230143923
PCT · Published · 2023-08 · Application PCT/KR2023/012409
PCT · Published · 2023-08 · Application PCT/KR2023/012411
Published · 2023-08 · Application 1020230109844
Published · 2023-08 · Application 1020230109456
PCT · Published · 2023-02 · Application PCT/KR2023/002546
Rejected · 2023-01 · Application 1020230007088
Published · 2022-11 · Application 1020220162803
Registered · 2022-09 · Application 1020220119471
Published · 2022-09 · Application 1020220118739
PCT · Published · 2022-08 · Application PCT/KR2022/012722
Registered · 2022-02 · Application 1020220025704
PCT · Published · 2021-09 · Application PCT/KR2021/012539
Rejected · 2021-09 · Application 1020210122724
Registered · 2021-09 · Application 1020210118637
PCT · Published · 2021-08 · Application PCT/KR2021/010827
Rejected · 2021-08 · Application 1020210107556
PCT · Published · 2021-05 · Application PCT/KR2021/006651
Rejected · 2021-05 · Application 1020210068189
PCT · Published · 2021-03 · Application PCT/KR2021/002604
Rejected · 2021-01 · Application 1020210012322
PCT · Published · 2021-01 · Application PCT/KR2021/000357
PCT · Published · 2021-01 · Application PCT/KR2021/000341
PCT · Published · 2021-01 · Application PCT/KR2021/000349
PCT · Published · 2020-09 · Application PCT/KR2020/012993
PCT · Published · 2020-09 · Application PCT/KR2020/012961
PCT · Published · 2020-09 · Application PCT/KR2020/012471
PCT · Published · 2020-09 · Application PCT/KR2020/012472
Published · 2020-06 · Application 1020200075802
Published · 2020-06 · Application 1020200075799
Published · 2020-06 · Application 1020200075800
Registered · 2020-04 · Application 1020200050694
PCT · Published · 2020-03 · Application PCT/KR2020/003601
Registered · 2020-02 · Application 1020200012960
Registered · 2020-01 · Application 1020200009029
PCT · Published · 2020-01 · Application PCT/KR2020/000891
Registered · 2020-01 · Application 1020200004401
Expired · 2020-01 · Application 1020200004414
Registered · 2019-12 · Application 1020190164435
Registered · 2019-12 · Application 1020190163945
Registered · 2019-11 · Application 1020190157158
Expired · 2019-10 · Application 1020190131785
Expired · 2019-10 · Application 1020190131784
PCT · Published · 2019-07 · Application PCT/KR2019/007964
TW · Registered · 2019-05 · Application 108119051
PCT · Published · 2019-04 · Application PCT/KR2019/004743
PCT · Published · 2019-04 · Application PCT/KR2019/004601
Registered · 2019-04 · Application 1020190044335
US · Registered · 2019-04 · Application 17047174
PCT · Published · 2019-04 · Application PCT/KR2019/004355
PCT · Published · 2019-04 · Application PCT/KR2019/004224
Expired · 2019-02 · Application 1020190015835
US · Registered · 2018-12 · Application 15733370
PCT · Published · 2018-12 · Application PCT/KR2018/016625
Registered · 2018-12 · Application 1020180156055
CN · Published · 2018-11 · Application 201880079811.1
US · Registered · 2018-11 · Application 16768805
PCT · Published · 2018-11 · Application PCT/KR2018/014610
Registered · 2018-08 · Application 1020180096354
Rejected · 2018-07 · Application 1020180077287
Registered · 2018-06 · Application 1020180069955
PCT · Published · 2018-06 · Application PCT/KR2018/006720
Registered · 2018-05 · Application 1020180061101
Registered · 2018-04 · Application 1020180047078
Registered · 2018-04 · Application 1020180043391
Registered · 2018-01 · Application 1020180003229
Registered · 2017-12 · Application 1020170172473
US · Registered · 2017-10 · Application 16343494
Expired · 2017-09 · Application 1020170117165
Expired · 2017-09 · Application 1020170117166
Expired · 2017-09 · Application 1020170116793
Expired · 2017-09 · Application 1020170116792
Expired · 2017-09 · Application 1020170116791
CN · Published · 2017-06 · Application 201780092503.8
US · Registered · 2017-06 · Application 16626410
Registered · 2017-06 · Application 1020170081320
Registered · 2017-06 · Application 1020170079941
Registered · 2017-06 · Application 1020170079937
Registered · 2017-06 · Application 1020170079938
Registered · 2017-06 · Application 1020170079939
Registered · 2017-06 · Application 1020170079936
Registered · 2017-06 · Application 1020170079940
CN · Published · 2017-03 · Application 201780018075.4
Registered · 2017-03 · Application 1020170033305
CN · Published · 2017-03 · Application 201780028153.9
US · Registered · 2017-02 · Application 16075519
EP · Published · 2017-02 · Application 17747784.1
US · Published · 2016-12 · Application 15385033
Registered · 2016-10 · Application 1020160137599
Rejected · 2016-10 · Application 1020160133819
Registered · 2016-10 · Application 1020160132897
Registered · 2016-10 · Application 1020160129227
CN · Published · 2016-06 · Application 201680049437.1
US · Registered · 2016-06 · Application 15739532
Registered · 2016-06 · Application 1020160080449
TW · Registered · 2016-05 · Application 105116842
Registered · 2016-03 · Application 1020160029881
Registered · 2016-02 · Application 1020160016588
Registered · 2016-02 · Application 1020160015306
Registered · 2015-11 · Application 1020150165457
Rejected · 2015-11 · Application 1020150164795
Registered · 2015-10 · Application 1020150150547
US · Registered · 2015-08 · Application 15504663
EP · Published · 2015-08 · Application 15834611.4
Registered · 2015-08 · Application 1020150116396
CN · Published · 2015-08 · Application 201580055280.9
CN · Published · 2015-08 · Application 202210667299.0
Registered · 2015-08 · Application 1020157022218
Withdrawn · 2015-06 · Application 1020150087128
Registered · 2015-05 · Application 1020150076665
Registered · 2015-05 · Application 1020150076256
CN · Published · 2014-12 · Application 201480029852
US · Published · 2014-12 · Application 14889619
EP · Published · 2014-12 · Application 14872706.8
TW · Registered · 2014-09 · Application 103131513
Expired · 2014-07 · Application 1020140085171
CN · Published · 2014-04 · Application 201480024332
EP · Published · 2014-04 · Application 14791495.6
CN · Published · 2014-03 · Application 201810516438.3
CN · Published · 2014-03 · Application 201480016211
US · Registered · 2014-03 · Application 14776386
EP · Registered · 2014-03 · Application 14764801.8
Registered · 2014-03 · Application 1020140030361
Expired · 2014-02 · Application 1020140021731
Expired · 2014-02 · Application 1020140015023
Registered · 2013-12 · Application 1020130164427
Registered · 2013-12 · Application 1020130164432
Registered · 2013-12 · Application 1020130164431
Registered · 2013-12 · Application 1020130164433
Rejected · 2013-12 · Application 1020130164434
Registered · 2013-12 · Application 1020130159980
Rejected · 2013-12 · Application 1020130152683
Rejected · 2013-10 · Application 1020130127571
Registered · 2013-05 · Application 1020130049002
Registered · 2013-04 · Application 1020130047566
CN · Published · 2013-04 · Application 201380025567
EP · Registered · 2013-04 · Application 13778634.9
Registered · 2013-01 · Application 1020130004525
CN · Published · 2012-08 · Application 201280053817
Rejected · 2012-04 · Application 1020120039907
Expired · 2012-04 · Application 1020120039708
Rejected · 2011-11 · Application 1020110124019
Registered · 2011-11 · Application 1020110113131
Rejected · 2011-08 · Application 1020110088206
CN · Published · 2011-06 · Application 201180026974
EP · Registered · 2011-06 · Application 11790010.0
Expired · 2011-05 · Application 1020110046560
Rejected · 2011-04 · Application 1020110041150
Expired · 2010-11 · Application 1020100108331
Expired · 2010-06 · Application 1020100061162
Registered · 2010-06 · Application 1020100052030
Rejected · 2010-06 · Application 1020100052031
US · Published · 2009-09 · Application 13255074
EP · Published · 2009-09 · Application 09841566.4
PCT · Published · 2009-09 · Application PCT/KR2009/005533
EP · Published · 2009-09 · Application 09849855.3
Rejected · 2009-09 · Application 1020090085380
CN · Published · 2009-04 · Application 200980156073
EP · Published · 2009-04 · Application 09839738.3
PCT · Published · 2009-04 · Application PCT/KR2009/002249
Expired · 2009-03 · Application 1020090020676
Registered · 2009-02 · Application 1020090008830
Expired · 2009-01 · Application 1020090004841
Rejected · 2009-01 · Application 1020090003376
Expired · 2009-01 · Application 1020090002408
Rejected · 2009-01 · Application 1020090002406
Registered · 2008-12 · Application 1020080122416
Expired · 2008-10 · Application 1020080096975
Registered · 2008-09 · Application 1020080086215
Registered · 2008-07 · Application 1020080069933
CN · Published · 2008-04 · Application 200880013722
EP · Published · 2008-04 · Application 08741500.6
Rejected · 2007-09 · Application 1020070094170
Expired · 2007-06 · Application 1020070064866
Expired · 2007-04 · Application 1020070041062
Expired · 2006-08 · Application 1020060081110
Expired · 2006-06 · Application 1020060060717
Expired · 2006-03 · Application 1020060021235
Expired · 2006-03 · Application 1020060021236
Expired · 2006-02 · Application 1020060017685
Rejected · 2006-02 · Application 1020060014437
Expired · 2006-02 · Application 1020060011048
Expired · 2006-02 · Application 1020060010730
Expired · 2005-11 · Application 1020050113318
Expired · 2005-05 · Application 1020050039503
Expired · 2005-02 · Application 1020050014306
Expired · 2005-02 · Application 1020050013849
Expired · 2005-02 · Application 1020050013848
Expired · 2005-02 · Application 1020050013099
Expired · 2005-02 · Application 1020050012161
Expired · 2005-02 · Application 1020050012162
Expired · 2005-02 · Application 1020050012163
Expired · 2004-11 · Application 1020040098117
Expired · 2004-11 · Application 1020040091203
Expired · 2004-10 · Application 1020040084429
Expired · 2004-07 · Application 1020040057450
Expired · 2004-07 · Application 1020040057706
Expired · 2004-07 · Application 1020040057656
Expired · 2004-06 · Application 1020040040625
Expired · 2004-06 · Application 1020040040623
Expired · 2004-06 · Application 1020040040624
Expired · 2004-03 · Application 1020040017871
Expired · 2004-01 · Application 1020040003203
Expired · 2004-01 · Application 1020040002846
Rejected · 2004-01 · Application 1020040002847
Expired · 2003-12 · Application 1020030092873
Expired · 2003-12 · Application 1020030092874
Expired · 2003-12 · Application 1020030086281
Rejected · 2003-10 · Application 1020030070177
Expired · 2003-10 · Application 1020030070176
Expired · 2003-09 · Application 1020030066488
Expired · 2003-09 · Application 1020030066487
Expired · 2003-08 · Application 1020030058494
Expired · 2003-08 · Application 1020030056819
Expired · 2003-08 · Application 1020030056818
Expired · 2003-07 · Application 1020030051358
Rejected · 2003-07 · Application 1020030051399
Expired · 2003-07 · Application 1020030051360
Expired · 2003-07 · Application 1020030045647
Expired · 2003-06 · Application 1020030041102
Rejected · 2003-06 · Application 1020030036187
Expired · 2003-05 · Application 1020030031070
PCT · Published · 2003-04 · Application PCT/KR2003/000835
PCT · Published · 2003-04 · Application PCT/KR2003/000813
Expired · 2003-04 · Application 1020030023565
Expired · 2003-03 · Application 1020030019890
Expired · 2003-03 · Application 1020030015149
Expired · 2003-03 · Application 1020030015148
Expired · 2003-02 · Application 1020030012729
Expired · 2003-02 · Application 1020030012730
Expired · 2003-02 · Application 1020030010405
Expired · 2002-11 · Application 1020020073301
Expired · 2002-11 · Application 1020020073300
Expired · 2002-08 · Application 1020020051116
Expired · 2002-07 · Application 1020020041137
Expired · 2002-06 · Application 1020020035945
Expired · 2002-06 · Application 1020020035946
Expired · 2002-05 · Application 1020020024146
Expired · 2002-03 · Application 1020020012250
Expired · 2002-02 · Application 1020020008971
Rejected · 2001-12 · Application 1020010086690
Expired · 2001-11 · Application 1020010070733
Expired · 2001-10 · Application 1020010065655
Expired · 2001-09 · Application 1020010055305
Expired · 2001-07 · Application 1020010043990
Rejected · 2001-03 · Application 1020010016272
Rejected · 2000-12 · Application 1020000085121
Expired · 2000-09 · Application 1020000054567
Expired · 2000-06 · Application 1020000034178
Expired · 2000-06 · Application 1020000034180
Rejected · 2000-04 · Application 1020000018318
Expired · 1999-11 · Application 1019990050584
Expired · 1999-09 · Application 1019990040080
Expired · 1999-06 · Application 1019990023425
Expired · 1999-03 · Application 1019990009929
Rejected · 1999-02 · Application 1019990006424
Expired · 1999-01 · Application 1019990002541
Rejected · 1997-08 · Application 1019970041364
Expired · 1997-07 · Application 1019970032806
Expired · 1997-05 · Application 1019970017802
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive3
- OpenAIOAI-SearchBot70
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 26, 2026 · 5 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for KOREA UNITED PHARM INC and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition